Efficacy of Megadose Vitamin C in Severe and Critical Ill COVID-19 Patients.

Summary

The main aim is to determine whether vitamin C can reduce 28-day all-cause mortality or persistent organ dysfunction compared with placebo in patients with severe and critical ill COVID-19 patients. Participants will randomly receive HIVC or placebo for 4 days once enrolled. The primary outcome is a composite of death or persistent organ dysfunction (defined as dependency on vasopressors, mechanical ventilation, or CRRT) at day 28 after randomization.

Timeline

Start

2023-01-13

Primary completion

2023-04

Completion

2023-06

Drugs

Indications